메뉴 건너뛰기




Volumn 9, Issue 7, 2007, Pages 547-560

Allogeneic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer - A phase I clinical trial

Author keywords

Cancer immunotherapy; Gene therapy; IFN ; IL 2; Prostate cancer; Tumor cell vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; GAMMA INTERFERON; GONADORELIN AGONIST; HLA A2 ANTIGEN; INTERLEUKIN 2; PROSTATE SPECIFIC ANTIGEN; RETROVIRUS VECTOR;

EID: 34447579117     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1051     Document Type: Article
Times cited : (21)

References (94)
  • 2
    • 33644848317 scopus 로고    scopus 로고
    • Hormone refractory prostate cancer: Management and advances
    • Sonpavde G, Hutson TE, Berry WR. Hormone refractory prostate cancer: management and advances. Cancer Treat Rev 2006; 32: 90-100.
    • (2006) Cancer Treat Rev , vol.32 , pp. 90-100
    • Sonpavde, G.1    Hutson, T.E.2    Berry, W.R.3
  • 3
    • 0038514138 scopus 로고    scopus 로고
    • Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
    • Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-1237.
    • (2003) J Clin Oncol , vol.21 , pp. 1232-1237
    • Halabi, S.1    Small, E.J.2    Kantoff, P.W.3
  • 4
    • 34447551019 scopus 로고    scopus 로고
    • Hormonal therapy for prostate cancer
    • Brawer MK. Hormonal therapy for prostate cancer. Rev Urol 2006; Suppl 2: S35-47.
    • (2006) Rev Urol , Issue.SUPPL. 2
    • Brawer, M.K.1
  • 5
    • 0037024461 scopus 로고    scopus 로고
    • Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?
    • Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002; 94: 805-818.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 805-818
    • Parmiani, G.1    Castelli, C.2    Dalerba, P.3
  • 6
    • 0037379265 scopus 로고    scopus 로고
    • Modulation of antitumor immune response by hematopoietic cytokines
    • Waller EK, Ernstoff MS. Modulation of antitumor immune response by hematopoietic cytokines. Cancer 2003; 97: 1797-1809.
    • (2003) Cancer , vol.97 , pp. 1797-1809
    • Waller, E.K.1    Ernstoff, M.S.2
  • 7
    • 33845741035 scopus 로고    scopus 로고
    • Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients
    • Alessandro S, Miriam L, Annamaria AG, et al. Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate 2007; 67: 1-7.
    • (2007) Prostate , vol.67 , pp. 1-7
    • Alessandro, S.1    Miriam, L.2    Annamaria, A.G.3
  • 8
    • 33751363704 scopus 로고    scopus 로고
    • Tumor escape mechanisms in prostate cancer
    • Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007; 56: 81-87.
    • (2007) Cancer Immunol Immunother , vol.56 , pp. 81-87
    • Miller, A.M.1    Pisa, P.2
  • 9
    • 0032433127 scopus 로고    scopus 로고
    • The central role of CD4(+) T cells in the antitumor immune response
    • Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368.
    • (1998) J Exp Med , vol.188 , pp. 2357-2368
    • Hung, K.1    Hayashi, R.2    Lafond-Walker, A.3
  • 10
    • 0034292406 scopus 로고    scopus 로고
    • Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses
    • Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000; 165: 3797-3803.
    • (2000) J Immunol , vol.165 , pp. 3797-3803
    • Nouri-Shirazi, M.1    Banchereau, J.2    Bell, D.3
  • 11
    • 0035963379 scopus 로고    scopus 로고
    • Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
    • Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411: 1058-1064.
    • (2001) Nature , vol.411 , pp. 1058-1064
    • Ochsenbein, A.F.1    Sierro, S.2    Odermatt, B.3
  • 12
    • 0037460070 scopus 로고    scopus 로고
    • Complementray role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells
    • Yu P, Spiotto MT, Lee Y, et al. Complementray role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med 2003; 197: 985-995.
    • (2003) J Exp Med , vol.197 , pp. 985-995
    • Yu, P.1    Spiotto, M.T.2    Lee, Y.3
  • 13
    • 0042629611 scopus 로고    scopus 로고
    • Elimination of CD4+ T cells may overcome suppression of anti-HER2 immune responses in tumor-bearing hosts
    • Ishihara M, Tawara I, Wang L, et al. Elimination of CD4+ T cells may overcome suppression of anti-HER2 immune responses in tumor-bearing hosts. Int J Oncol 2003; 22: 1135-1139.
    • (2003) Int J Oncol , vol.22 , pp. 1135-1139
    • Ishihara, M.1    Tawara, I.2    Wang, L.3
  • 14
    • 31144469922 scopus 로고    scopus 로고
    • Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines
    • Dolan BP, Gibbs KD, Ostrand-Rosenberg S. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J Immunol 2006; 176: 1447-1455.
    • (2006) J Immunol , vol.176 , pp. 1447-1455
    • Dolan, B.P.1    Gibbs, K.D.2    Ostrand-Rosenberg, S.3
  • 16
    • 3042844293 scopus 로고    scopus 로고
    • Cancer immunotherapy: A treatment for the masses
    • Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004; 305: 200-205.
    • (2004) Science , vol.305 , pp. 200-205
    • Blattman, J.N.1    Greenberg, P.D.2
  • 17
    • 33644697100 scopus 로고    scopus 로고
    • Prostate cancer immunology: Biology, therapeutics, and challenges
    • Webster WS, Small EJ, Rini B, et al. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol 2005; 23: 8262-8269.
    • (2005) J Clin Oncol , vol.23 , pp. 8262-8269
    • Webster, W.S.1    Small, E.J.2    Rini, B.3
  • 18
    • 20444467359 scopus 로고    scopus 로고
    • Technology Insight: Vaccine therapy for prostate cancer
    • Vieweg J, Dannull J. Technology Insight: vaccine therapy for prostate cancer. Nat Clin Pract Urol 2005; 2: 244-251.
    • (2005) Nat Clin Pract Urol , vol.2 , pp. 244-251
    • Vieweg, J.1    Dannull, J.2
  • 19
    • 33644638927 scopus 로고    scopus 로고
    • MDX-010 (human anti-CTLA4): A phase 1 trial in hormone refractory prostate carcinoma (HRPC) [Abstract 74]
    • Davis TA, Tchekmedyian S, Korman A, et al. MDX-010 (human anti-CTLA4): a phase 1 trial in hormone refractory prostate carcinoma (HRPC) [Abstract 74]. Am Soc Clin Oncol 2002.
    • (2002) Am Soc Clin Oncol
    • Davis, T.A.1    Tchekmedyian, S.2    Korman, A.3
  • 20
    • 4644253363 scopus 로고    scopus 로고
    • International meeting on cancer vaccines: How can we enhance efficacy of therapeutic vaccines?
    • Belardelli F, Ferrantini M, Parmiani G, et al. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 2004; 64: 6827-6830.
    • (2004) Cancer Res , vol.64 , pp. 6827-6830
    • Belardelli, F.1    Ferrantini, M.2    Parmiani, G.3
  • 21
    • 32944474058 scopus 로고    scopus 로고
    • Effective cancer therapy through immunomodulation
    • Waldmann TA. Effective cancer therapy through immunomodulation. Annu Rev Med 2006; 57: 65-81.
    • (2006) Annu Rev Med , vol.57 , pp. 65-81
    • Waldmann, T.A.1
  • 22
    • 0030470404 scopus 로고    scopus 로고
    • Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
    • Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371-380.
    • (1996) Prostate , vol.29 , pp. 371-380
    • Murphy, G.1    Tjoa, B.2    Ragde, H.3
  • 23
    • 0032526296 scopus 로고    scopus 로고
    • Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
    • Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36: 39-44.
    • (1998) Prostate , vol.36 , pp. 39-44
    • Tjoa, B.A.1    Simmons, S.J.2    Bowes, V.A.3
  • 24
    • 0033987088 scopus 로고    scopus 로고
    • Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients
    • Murphy GP, Snow P, Simmons SJ, et al. Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients. Prostate 2000; 42: 67-72.
    • (2000) Prostate , vol.42 , pp. 67-72
    • Murphy, G.P.1    Snow, P.2    Simmons, S.J.3
  • 25
    • 0034043167 scopus 로고    scopus 로고
    • Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
    • Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6: 2175-2182.
    • (2000) Clin Cancer Res , vol.6 , pp. 2175-2182
    • Burch, P.A.1    Breen, J.K.2    Buckner, J.C.3
  • 26
    • 0034554863 scopus 로고    scopus 로고
    • Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
    • Small F.J, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-3903.
    • (2000) J Clin Oncol , vol.18 , pp. 3894-3903
    • Small, F.J.1    Fratesi, P.2    Reese, D.M.3
  • 27
    • 33646914157 scopus 로고    scopus 로고
    • Immunologic targeting: How to channel a minimal response for maximal outcome
    • Slovin SF. Immunologic targeting: how to channel a minimal response for maximal outcome. Curr Opin Urol 2006; 16: 179-185.
    • (2006) Curr Opin Urol , vol.16 , pp. 179-185
    • Slovin, S.F.1
  • 28
    • 0036888238 scopus 로고    scopus 로고
    • Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients
    • Kiessling A, Schmitz M, Stevanovic S, et al. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 2002; 102: 390-397.
    • (2002) Int J Cancer , vol.102 , pp. 390-397
    • Kiessling, A.1    Schmitz, M.2    Stevanovic, S.3
  • 29
    • 0037244743 scopus 로고    scopus 로고
    • Rational approaches to human cancer immunotherapy
    • Davis ID, Jefford M, Parente P, et al. Rational approaches to human cancer immunotherapy. J Leukoc Biol 2003; 73: 3-29.
    • (2003) J Leukoc Biol , vol.73 , pp. 3-29
    • Davis, I.D.1    Jefford, M.2    Parente, P.3
  • 30
    • 2942559009 scopus 로고    scopus 로고
    • Cancer immunotherapy with mRNA-transfected dendritic cells
    • Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004; 199: 251-263.
    • (2004) Immunol Rev , vol.199 , pp. 251-263
    • Gilboa, E.1    Vieweg, J.2
  • 31
    • 15844420469 scopus 로고    scopus 로고
    • Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer
    • Schellhammer PF, Hershberg RM. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol 2005; 23: 47-49.
    • (2005) World J Urol , vol.23 , pp. 47-49
    • Schellhammer, P.F.1    Hershberg, R.M.2
  • 32
    • 0037441817 scopus 로고    scopus 로고
    • How can we tell when cancer vaccines vaccinate
    • Wolchok JD. How can we tell when cancer vaccines vaccinate. J Clin Oncol 2003; 4: 586-587.
    • (2003) J Clin Oncol , vol.4 , pp. 586-587
    • Wolchok, J.D.1
  • 33
    • 3242747658 scopus 로고    scopus 로고
    • Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase 2 trial
    • Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004; 60: 197-204.
    • (2004) Prostate , vol.60 , pp. 197-204
    • Burch, P.A.1    Croghan, G.A.2    Gastineau, D.A.3
  • 34
    • 4143110212 scopus 로고    scopus 로고
    • Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: A phase I trial in metastatic melanoma
    • Di Nicola M, Carlo-Stella C, Mortarini R, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res 2004; 10: 5381-5390.
    • (2004) Clin Cancer Res , vol.10 , pp. 5381-5390
    • Di Nicola, M.1    Carlo-Stella, C.2    Mortarini, R.3
  • 35
    • 4344637057 scopus 로고    scopus 로고
    • Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: A phase I/II study
    • Pandha HS, John RJ, Hutchinson J, et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 2004; 94: 412-418.
    • (2004) BJU Int , vol.94 , pp. 412-418
    • Pandha, H.S.1    John, R.J.2    Hutchinson, J.3
  • 36
    • 27144507469 scopus 로고    scopus 로고
    • Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
    • Mu LJ, Kyte K, Kkvalheim G, et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005; 93: 749-756.
    • (2005) Br J Cancer , vol.93 , pp. 749-756
    • Mu, L.J.1    Kyte, K.2    Kkvalheim, G.3
  • 37
    • 0034328925 scopus 로고    scopus 로고
    • Gene therapy: Trials and tribulations
    • Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1: 91-99.
    • (2000) Nat Rev Genet , vol.1 , pp. 91-99
    • Somia, N.1    Verma, I.M.2
  • 39
    • 33751204733 scopus 로고    scopus 로고
    • Gene therapy. An ethical profile of a new medical territory
    • DOI:10.1002/jgm.979
    • Fuchs M. Gene therapy. An ethical profile of a new medical territory. J Gene Med 2006; 8: 1358-1362. DOI:10.1002/jgm.979.
    • (2006) J Gene Med , vol.8 , pp. 1358-1362
    • Fuchs, M.1
  • 40
    • 0034800323 scopus 로고    scopus 로고
    • Gentherapie beim Prostatakarzinom
    • Brill T, Barba M, Breul J, et al. Gentherapie beim Prostatakarzinom. Internist (Berl) 2001; 42: 1328-1345.
    • (2001) Internist (Berl) , vol.42 , pp. 1328-1345
    • Brill, T.1    Barba, M.2    Breul, J.3
  • 41
    • 0035346833 scopus 로고    scopus 로고
    • In situ gene therapy for prostate cancer: Immunomodulatory approaches
    • Thompson TC, Timme TL, Ebara S, et al. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther 2001; 1: 481-495.
    • (2001) Expert Opin Biol Ther , vol.1 , pp. 481-495
    • Thompson, T.C.1    Timme, T.L.2    Ebara, S.3
  • 42
    • 0036324470 scopus 로고    scopus 로고
    • Gene therapy of prostate cancer: Current and future directions
    • Mabjeesh NJ, Zhong H, Simons JW. Gene therapy of prostate cancer: current and future directions. Endnocrine-Related Cancer 2002; 9: 115-139.
    • (2002) Endnocrine-Related Cancer , vol.9 , pp. 115-139
    • Mabjeesh, N.J.1    Zhong, H.2    Simons, J.W.3
  • 44
    • 4043082727 scopus 로고    scopus 로고
    • Gene-based therapy in prostate cancer
    • Foley R, Lawler M, Hollywood D. Gene-based therapy in prostate cancer. Lancet Oncol 2004; 5: 469-479.
    • (2004) Lancet Oncol , vol.5 , pp. 469-479
    • Foley, R.1    Lawler, M.2    Hollywood, D.3
  • 45
    • 0034171011 scopus 로고    scopus 로고
    • Gene therapy for prostate cancer at the University of California, Los Angeles: Preliminary results and future directions
    • Pantuck AJ, Zisman A, Belldegrun AS. Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions. World J Urol 2000; 18: 143-147.
    • (2000) World J Urol , vol.18 , pp. 143-147
    • Pantuck, A.J.1    Zisman, A.2    Belldegrun, A.S.3
  • 46
    • 0034927685 scopus 로고    scopus 로고
    • Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology
    • Belldegrun A, Tso CL, Zisman A, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001; 12: 883-892.
    • (2001) Hum Gene Ther , vol.12 , pp. 883-892
    • Belldegrun, A.1    Tso, C.L.2    Zisman, A.3
  • 47
    • 0035199415 scopus 로고    scopus 로고
    • Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy
    • Miles BJ, Shalev M, Aguilar-Cordova E, et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 2001; 12: 1955-1967.
    • (2001) Hum Gene Ther , vol.12 , pp. 1955-1967
    • Miles, B.J.1    Shalev, M.2    Aguilar-Cordova, E.3
  • 48
    • 0028153727 scopus 로고
    • Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs
    • Rosenthal FM, Cronin K, Bannerji R, et al. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs. Blood 1994; 83: 1289-1298.
    • (1994) Blood , vol.83 , pp. 1289-1298
    • Rosenthal, F.M.1    Cronin, K.2    Bannerji, R.3
  • 49
    • 12244280810 scopus 로고    scopus 로고
    • Low-dose IFN-γ induces tumor MHC expression in metastatic malignant melanoma
    • Propper DJ, Chao D, Braybrooke JP, et al. Low-dose IFN-γ induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res 2003; 9: 84-92.
    • (2003) Clin Cancer Res , vol.9 , pp. 84-92
    • Propper, D.J.1    Chao, D.2    Braybrooke, J.P.3
  • 50
    • 0037843509 scopus 로고    scopus 로고
    • Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge
    • Krishnan L, Sad S, Patel GB, et al. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res 2003; 63: 2526-2534.
    • (2003) Cancer Res , vol.63 , pp. 2526-2534
    • Krishnan, L.1    Sad, S.2    Patel, G.B.3
  • 51
    • 0034699775 scopus 로고    scopus 로고
    • Cytokine-modulated regulation of helper T cell populations
    • Yates A, Bergmann C, Van Hemmen JL, et al. Cytokine-modulated regulation of helper T cell populations. J Theor Biol 2000; 206: 539-560.
    • (2000) J Theor Biol , vol.206 , pp. 539-560
    • Yates, A.1    Bergmann, C.2    Van Hemmen, J.L.3
  • 53
    • 33745224089 scopus 로고    scopus 로고
    • Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells
    • Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006; 441: 890-893.
    • (2006) Nature , vol.441 , pp. 890-893
    • Williams, M.A.1    Tyznik, A.J.2    Bevan, M.J.3
  • 54
    • 20144389834 scopus 로고    scopus 로고
    • Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs
    • Frankenberger B, Pohla H, Noessner E, et al. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs. Clin Cancer Res 2005; 11: 1733-1742.
    • (2005) Clin Cancer Res , vol.11 , pp. 1733-1742
    • Frankenberger, B.1    Pohla, H.2    Noessner, E.3
  • 55
    • 20944441967 scopus 로고    scopus 로고
    • Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
    • Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005; 11: 3353-3362.
    • (2005) Clin Cancer Res , vol.11 , pp. 3353-3362
    • Gulley, J.L.1    Arlen, P.M.2    Bastian, A.3
  • 56
    • 0026541909 scopus 로고
    • Phase I trial of interleukin-2 plus gamma-interferon
    • Margolin KA, Doroshow JH, Akman SA, et al. Phase I trial of interleukin-2 plus gamma-interferon. J Immunother 1992; 11: 50-55.
    • (1992) J Immunother , vol.11 , pp. 50-55
    • Margolin, K.A.1    Doroshow, J.H.2    Akman, S.A.3
  • 57
    • 0029871645 scopus 로고    scopus 로고
    • Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma
    • Kim CJ, Taubenberger JK, Simonis TB, et al. Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma. J Immunother Emphasis Tumor Immunol 1996; 19: 50-58.
    • (1996) J Immunother Emphasis Tumor Immunol , vol.19 , pp. 50-58
    • Kim, C.J.1    Taubenberger, J.K.2    Simonis, T.B.3
  • 58
    • 0033587173 scopus 로고    scopus 로고
    • Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma
    • Palmer K, Moore J, Everard M, et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther 1999; 10: 1261-1268.
    • (1999) Hum Gene Ther , vol.10 , pp. 1261-1268
    • Palmer, K.1    Moore, J.2    Everard, M.3
  • 59
    • 0034671326 scopus 로고    scopus 로고
    • Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil
    • Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 2000; 18: 4009-4015.
    • (2000) J Clin Oncol , vol.18 , pp. 4009-4015
    • Negrier, S.1    Caty, A.2    Lesimple, T.3
  • 60
    • 0035914255 scopus 로고    scopus 로고
    • IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: Long-term results of a controlled randomized clinical trial
    • Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85: 1130-1136.
    • (2001) Br J Cancer , vol.85 , pp. 1130-1136
    • Atzpodien, J.1    Kirchner, H.2    Illiger, H.J.3
  • 61
    • 0342368610 scopus 로고    scopus 로고
    • Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma
    • de Gast GC, Klumpen HJ, Vyth-Dreese FA, et al. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 2000; 6: 1267-1272.
    • (2000) Clin Cancer Res , vol.6 , pp. 1267-1272
    • de Gast, G.C.1    Klumpen, H.J.2    Vyth-Dreese, F.A.3
  • 62
    • 0032741439 scopus 로고    scopus 로고
    • Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
    • Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59: 5160-5168.
    • (1999) Cancer Res , vol.59 , pp. 5160-5168
    • Simons, J.W.1    Mikhak, B.2    Chang, J.F.3
  • 63
    • 0033765794 scopus 로고    scopus 로고
    • Cancer cells engineered to secrete granulocyte-macrophage colonystimulatihg factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies
    • Nelson WG, Simons JW, Mikhak B, et al. Cancer cells engineered to secrete granulocyte-macrophage colonystimulatihg factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000; 46: S67-S72.
    • (2000) Cancer Chemother Pharmacol , vol.46
    • Nelson, W.G.1    Simons, J.W.2    Mikhak, B.3
  • 64
    • 0036164844 scopus 로고    scopus 로고
    • Allogeneic whole-cell vaccine: A phase I/II study in men with hormone-refractory prostate cancer
    • Eaton JD, Perry MJ, Nicholson S, et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 2002; 89: 19-26.
    • (2002) BJU Int , vol.89 , pp. 19-26
    • Eaton, J.D.1    Perry, M.J.2    Nicholson, S.3
  • 65
    • 0037673064 scopus 로고    scopus 로고
    • Genomic medicines for oncology: Early lessons
    • Simons JW. Genomic medicines for oncology: early lessons. J Med Assoc Ga 2003; 92: 35-38.
    • (2003) J Med Assoc Ga , vol.92 , pp. 35-38
    • Simons, J.W.1
  • 66
    • 20444453277 scopus 로고    scopus 로고
    • Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables
    • Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005; 11: 4469-4478.
    • (2005) Clin Cancer Res , vol.11 , pp. 4469-4478
    • Michael, A.1    Ball, G.2    Quatan, N.3
  • 68
    • 33748162994 scopus 로고    scopus 로고
    • Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer
    • Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 2006; 24: 419-424.
    • (2006) Urol Oncol , vol.24 , pp. 419-424
    • Simons, J.W.1    Sacks, N.2
  • 69
    • 33746012881 scopus 로고    scopus 로고
    • Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
    • Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094.
    • (2006) J Clin Oncol , vol.24 , pp. 3089-3094
    • Small, E.J.1    Schellhammer, P.F.2    Higano, C.S.3
  • 70
    • 34447537131 scopus 로고    scopus 로고
    • Available:, accessed: 29 Dec. 2006
    • Available: www4.od.nih.gov/oba/rac/protocol.pdf (accessed: 29 Dec. 2006).
  • 71
    • 0027203411 scopus 로고
    • Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
    • Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566-1572.
    • (1993) J Clin Oncol , vol.11 , pp. 1566-1572
    • Scher, H.I.1    Kelly, W.K.2
  • 72
    • 1442290324 scopus 로고    scopus 로고
    • Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the Prostate-Specific Antigen Working Group
    • Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22: 537-556.
    • (2004) J Clin Oncol , vol.22 , pp. 537-556
    • Scher, H.I.1    Eisenberger, M.2    D'Amico, A.V.3
  • 73
    • 0037108840 scopus 로고    scopus 로고
    • Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen
    • Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002; 62: 5807-5812.
    • (2002) Cancer Res , vol.62 , pp. 5807-5812
    • Lu, J.1    Celis, E.2
  • 74
    • 0030834459 scopus 로고    scopus 로고
    • MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma
    • Bander NH, Yao D, Liu H, et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997; 33: 233-239.
    • (1997) Prostate , vol.33 , pp. 233-239
    • Bander, N.H.1    Yao, D.2    Liu, H.3
  • 75
    • 0037252386 scopus 로고    scopus 로고
    • Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: Implications for gene therapy strategies
    • Pandha HS, Stockwin LH, Eaton J, et al. Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies. Prostate Cancer Prostatic Dis 2003; 6: 6-11.
    • (2003) Prostate Cancer Prostatic Dis , vol.6 , pp. 6-11
    • Pandha, H.S.1    Stockwin, L.H.2    Eaton, J.3
  • 76
    • 0034109776 scopus 로고    scopus 로고
    • Resistance to lysis by cytotoxic T cells: A dominant effect in metastatic mouse prostate cancer cells
    • Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 2000; 60: 1927-1933.
    • (2000) Cancer Res , vol.60 , pp. 1927-1933
    • Lee, H.M.1    Timme, T.L.2    Thompson, T.C.3
  • 77
    • 33750341482 scopus 로고    scopus 로고
    • Dendritic cells cross-dressed with peptide MHC Class I complexes prime CD8+ T Cells
    • Dolan BP, Gibbs KD Jr., Ostrand-Rosenberg S. Dendritic cells cross-dressed with peptide MHC Class I complexes prime CD8+ T Cells. J Immunol 2006; 177: 6018-6024.
    • (2006) J Immunol , vol.177 , pp. 6018-6024
    • Dolan, B.P.1    Gibbs Jr., K.D.2    Ostrand-Rosenberg, S.3
  • 78
    • 34447525833 scopus 로고    scopus 로고
    • Available:, accessed: 29 Dec. 2006
    • Available: www.syfpeithi.de (accessed: 29 Dec. 2006).
  • 79
    • 0032530575 scopus 로고    scopus 로고
    • Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide
    • Correale P, Walmsley K, Zaremba S, et al. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998; 161: 3186-3194.
    • (1998) J Immunol , vol.161 , pp. 3186-3194
    • Correale, P.1    Walmsley, K.2    Zaremba, S.3
  • 80
    • 0031895770 scopus 로고    scopus 로고
    • Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
    • Salgaller ML, Lodge PA, McLean JG, et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 1998; 35: 144-151.
    • (1998) Prostate , vol.35 , pp. 144-151
    • Salgaller, M.L.1    Lodge, P.A.2    McLean, J.G.3
  • 81
    • 0034306972 scopus 로고    scopus 로고
    • Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer
    • Dannull J, Diener PA, Prilder L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000; 60: 5522-5528.
    • (2000) Cancer Res , vol.60 , pp. 5522-5528
    • Dannull, J.1    Diener, P.A.2    Prilder, L.3
  • 82
    • 0035874893 scopus 로고    scopus 로고
    • Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule
    • Trojan A, Witzens M, Schultze JL, et al. Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res 2001; 61: 4761-4765.
    • (2001) Cancer Res , vol.61 , pp. 4761-4765
    • Trojan, A.1    Witzens, M.2    Schultze, J.L.3
  • 83
    • 22244458905 scopus 로고    scopus 로고
    • Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy
    • Machlenkin A, Paz A, Bar Haim E, et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005; 65: 6435-6442.
    • (2005) Cancer Res , vol.65 , pp. 6435-6442
    • Machlenkin, A.1    Paz, A.2    Bar Haim, E.3
  • 84
    • 0035182192 scopus 로고    scopus 로고
    • Efficient identification of novel HLA-A(*) 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis
    • Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(*) 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001; 193: 73-88.
    • (2001) J Exp Med , vol.193 , pp. 73-88
    • Kessler, J.H.1    Beekman, N.J.2    Bres-Vloemans, S.A.3
  • 85
    • 0033916550 scopus 로고    scopus 로고
    • Allogeneic vaccination for renal cell carcinoma: Development and monitoring
    • Pohla H, Frankenberger B, Stadlbauer B, et al. Allogeneic vaccination for renal cell carcinoma: development and monitoring. Bone Marrow Transplant 2000; 25(Suppl 2): S83-87.
    • (2000) Bone Marrow Transplant , vol.25 , Issue.SUPPL. 2
    • Pohla, H.1    Frankenberger, B.2    Stadlbauer, B.3
  • 86
    • 0037408535 scopus 로고    scopus 로고
    • Analysis of signal transducer and activator of transcription 3 (Stat3) pathway in multiple myeloma: Stat3 activation and cyclin D1 overexpression are mutually exclusive events
    • Quintanilla-Martinez L, Kremer M, Specht K, et al. Analysis of signal transducer and activator of transcription 3 (Stat3) pathway in multiple myeloma: Stat3 activation and cyclin D1 overexpression are mutually exclusive events. Am J Pathol 2003; 162: 1449-1461.
    • (2003) Am J Pathol , vol.162 , pp. 1449-1461
    • Quintanilla-Martinez, L.1    Kremer, M.2    Specht, K.3
  • 87
    • 0036896972 scopus 로고    scopus 로고
    • Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine
    • Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002; 20: 4549-4554.
    • (2002) J Clin Oncol , vol.20 , pp. 4549-4554
    • Hsueh, E.C.1    Essner, R.2    Foshag, L.J.3
  • 88
    • 10744230275 scopus 로고    scopus 로고
    • Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial
    • Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363: 594-599.
    • (2004) Lancet , vol.363 , pp. 594-599
    • Jocham, D.1    Richter, A.2    Hoffmann, L.3
  • 89
    • 22144497779 scopus 로고    scopus 로고
    • Vaccines in cancer: GVAX, a GM-CSF gene vaccine
    • Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines 2005; 4: 259-274.
    • (2005) Expert Rev Vaccines , vol.4 , pp. 259-274
    • Nemunaitis, J.1
  • 90
    • 22544458183 scopus 로고    scopus 로고
    • Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer
    • Beinart G, Rini BI, Weinberg V, et al. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005; 4: 55-60.
    • (2005) Clin Prostate Cancer , vol.4 , pp. 55-60
    • Beinart, G.1    Rini, B.I.2    Weinberg, V.3
  • 91
    • 2542574206 scopus 로고    scopus 로고
    • CD8+ T cell cross-priming via transfer of proteasome substrates
    • Norbury CC, Basta S, Donohue KB, et al. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 2004; 304: 1318-1321.
    • (2004) Science , vol.304 , pp. 1318-1321
    • Norbury, C.C.1    Basta, S.2    Donohue, K.B.3
  • 92
    • 1542357672 scopus 로고    scopus 로고
    • Cellular protein is the source of cross-priming antigen in vivo
    • Shen L, Rock KL. Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci U S A 2004; 101: 3035-3040.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 3035-3040
    • Shen, L.1    Rock, K.L.2
  • 93
    • 0035554675 scopus 로고    scopus 로고
    • The risk of autoimmunity associated with tumor immunotherapy
    • Gilboa E. The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2001; 2: 789-792.
    • (2001) Nat Immunol , vol.2 , pp. 789-792
    • Gilboa, E.1
  • 94
    • 0031255311 scopus 로고    scopus 로고
    • Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer
    • Fong L, Ruegg CL, Brockstedt D, et al. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997; 159: 3113-3117.
    • (1997) J Immunol , vol.159 , pp. 3113-3117
    • Fong, L.1    Ruegg, C.L.2    Brockstedt, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.